Congress meeting · Dr. Gabriel Ueda

17 Mar 2026 · Phone · Dr. Gabriel Ueda, Institut Curie · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0006MI request

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Comparator checkpoint monotherapy
Sequencing after progression

Scientific content used

PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Congress meeting with pathologist at Institut Curie. Discussed pd-l1 testing turnaround, comparator checkpoint monotherapy, sequencing after progression.

Insights captured (1)

Capture insight

INS-0038Medium
PD-L1 testing turnaround
PD-L1 testing turnaround: request for data reported by pathologist (FR).
Archived

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 3
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0006

Audit history (0)

All create, update and approval events for this record

No audit events in sample data